Navigation Links
UCI gets major funding to study ways of preventing drug-resistant staph infections

Irvine, Calif., Oct. 1, 2010 A UC Irvine infectious disease specialist has received a three-year, $10 million grant to explore the effectiveness of new methods to prevent staph infections in people who harbor MRSA bacteria when they're discharged from the hospital.

The federal Agency for Healthcare Research & Quality awarded Huang the grant as part of its CHOICE program, which is funded by American Recovery & Reinvestment Act of 2009. CHOICE grants will support large projects in comparative effectiveness research to aid decision making in priority areas of clinical care. Selected studies are deemed likely to result in major healthcare advances.

The UCI study, led by Dr. Susan Huang medical director of epidemiology & infection prevention at UC Irvine Medical Center and a UCI Health Policy Research Institute affiliate may provide the first post-discharge preventative treatments for the 1.8 million Americans each year who carry the methicillin-resistant Staphylococcus aureus bacteria.

MRSA is highly contagious and resistant to the antibiotics used in ordinary staph infections. Most MRSA cases occur in people who've recently been in the hospital or another healthcare setting, such as a nursing home or dialysis center. About 25 percent of patients with MRSA will develop an infection within a year of discharge. These infections require costly medical attention, including frequent hospital readmission.

"While prior studies have focused on preventing transmission, our effort will fill the large and important gap of how to prevent infection in the growing number of people who already harbor MRSA," Huang said. "Identification of an effective strategy to reduce MRSA infection and hospitalization would be a major advancement in clinical care."

Project CLEAR Changing Lives by Eradicating Antibiotic Resistance involves a randomized trial at hospitals in Orange County and southeast Los Angeles County comparing the efficacy of antibacterial nasal ointments, mouth rinses and body washes among patients carrying MRSA upon hospital discharge.

Additionally, the project will assess the medical and nonmedical costs of MRSA infections and quantify the potential savings attributable to different preventative treatments.

"MRSA containment and eradication is a national priority because of its virulence and rapid expansion in healthcare settings," Huang said. "This trial will provide a critically needed comprehensive evaluation of strategies to decrease MRSA infection risk across the continuum of inpatient and outpatient care."

Through its Health Policy Research Institute, UCI has become a nationwide leader in comparative effectiveness research, which explores the best possible treatment options for patients, based on criteria like age, gender, race and health history.

In 2009, the center's co-executive director, Dr. Sheldon Greenfield, helped chair an influential Institute of Medicine panel charged with advising the government on how to spend money allocated by Congress for comparative effectiveness research. It crafted a list of 100 healthcare priorities such as heart disease, Alzheimer's and cancer that became the foundation of the CHOICE program and related initiatives.

Greenfield also is co-investigator on two CHOICE-funded projects: A Vanderbilt University-led effort will identify the best use of radiation or surgery for various forms of prostate cancer. And one headed by UCLA will examine different approaches to congestive heart failure that limit the need for hospitalization.

"The commitment by the federal government to CHOICE and other comparative effectiveness programs will usher in new forms of research, leading to more effective personal care," said Greenfield, Donald Bren Professor of Medicine at UCI. "It ultimately will produce more tools for the physician and more options for the patient."


Contact: Tom Vasich
University of California -- Irvine

Related medicine news :

1. Lack of trust in hospitals a major deterrent for blood donation among African-Americans
2. Choice of career is a major risk factor for persistent neurodermatitis
3. Study findings show value of dietary supplement SAMe in treatment of adults with major depressive disorders
4. Lower-dose heparin use during coronary procedure does not appear to reduce risk of major bleeding
5. New partnership fosters broad scientific exchange with major Chinese university, hospital
6. Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection
7. University of Colorado joins forces with major research affiliate
8. University of Colorado joins with major research firm to partner on stem cell research
9. New research finds major activation themes in denture-stomatitis
10. UC San Diego receives major clinical and translational science award
11. Study shows that major Alzheimers risk gene causes alterations in shapes of brain protein deposits
Post Your Comments:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
Breaking Medicine Technology: